Nvidia

GetQuin and my current frustration

Time for a bit of mimimi and an opinion poll.

For some time now, less and less has been working for me with GetQuin. Portfolios are not updated, brokers are not available, and entire performance limitations on the part of GetQuin are (please correct me) not communicated.

1) CSV import

CSV, the simplest output of almost every broker, cannot be imported into GetQuin (anymore?). How can that be! Am I supposed to type and enter 120+ transactions by hand? Without any certainty that something will not be messed up again in the future and I will have to enter everything manually again? In my opinion, this needs to be solved as quickly as possible... And also a corresponding export as CSV.

2) Lack of up-to-dateness

While Shitcoins are offered on a daily basis, Swiss titles are still missing ($RSGN as just one example is always delayed or only updated once a day...) and the consideration of local circumstances (e.g. capital repayment vs. dividend, withholding tax, other stock exchanges, etc.).

3) Coins

The incentive system for community support is well-intentioned, but seems to lead to even more garbage being published just to collect coins. Hopefully this is just a short term trend. (Writing code to automatically publish generic GPT requests would not be particularly expensive per token, nor would it be particularly laborious... But the incentive is created... )

4) Thematic posts and filters

Crypto crypto , shares, other, crypto, other, women GIFs, crypto, shares, 5x $NVDA (+2.92%) in a row with the same content, and crypto again.

This is roughly the sequence of posts. Can I PLEASE have a filter to hide thematic posts? Or shouldn't a simple algorithm remember which posts I spend time on?

5) Reactions

What good is it if the community punishes bad posts with 🆘 "SOS", but these reactions have no negative effects on the performance of the post or the author? Let's filter garbage or incorrect content this way.

6) What do you want for development posts?

GetQuin asks the community what they want. We get in touch. And then nothing happens? I still don't understand that. So many old comments from users contain insane ideas with huge support and many responses - but then these remain undeveloped? GetQuin has (public sources, therefore not "100% sure") raised over 15 million in venture capital - plus our membership fees and (yuck) advertising partners (influencers and bloggers). Surely a little more development work should be possible? Or is a quick cashout and Bali/Dubai planned?

Is there anything that bothers you? Let's collect a bit.

Happy Investing

-----------

Sorry:

$NVDA (+2.92%)
$MSTR (-15.15%)
$SMCI
$BTC (+4.46%)
$ETH (+9.16%)
$SOL
$MSFT (+0.15%)
$GOOGL (-4.57%)
$GOOG (-4.5%)

Nvidia
$NVDA (+2.92%) and Microsoft
$MSFT (+0.15%) today announced new product integrations designed to "support the comprehensive development of NVIDIA AI on Microsoft platforms and in their applications".

This shows $NVDA (+2.92%) how unimportant the short-term reactions immediately after earnings are. It looks as if people have slept on the figures until something happens. But of course today's rise is also just background noise. Even if it sounds a bit more "harmonious".

EDIT: And even as I'm writing this, my view is being confirmed: just 5 percent up, now only 2 percent.

EDIT DES EDIT: And - poof - only 1 percent.

Analyst updates, 21.11.

⬆️⬆️⬆️

- BERNSTEIN RAISES TARGET FOR NVIDIA TO USD 175 (155) - 'OUTPERFORM' $NVDA (+2.92%)

- JPMORGAN RAISES TARGET FOR NVIDIA TO 170 (155) USD - 'OVERWEIGHT' $NVDA (+2.92%)

- EVERCORE ISI RAISES TARGET FOR NVIDIA TO 190 (189) USD - 'OUTPERFORM' $NVDA (+2.92%)

- JEFFERIES RAISES TARGET FOR SIXT STEMS TO EUR 110 (100) - 'BUY' $SIX2 (-0.99%)

- DEUTSCHE BANK RESEARCH RAISES RHEINMETALL TO 'BUY' (HOLD) - TARGET 700 (550) EUR $RHM (+1.35%)

- BARCLAYS RAISES TARGET FOR FRESENIUS SE TO EUR 40 (38) - 'OVERWEIGHT' $FRE (+2.58%)

- WARBURG RESEARCH raises the target price for ALSTRIA OFFICE from EUR 3.40 to EUR 7.10. Hold. $AOX (-2.22%)

- BERNSTEIN raises the price target for ESSILORLUXOTTICA from EUR 194 to EUR 200. Market-Perform. $EL (-1.33%)

⬇️⬇️⬇️

- DEUTSCHE BANK RESEARCH lowers the price target for NESTLE from CHF 87 to CHF 85. Hold. $NESN (-0.29%)

- DEUTSCHE BANK RESEARCH lowers the price target for MEDIOS from EUR 23 to EUR 18. Buy. $ILM1 (-4.65%)

- ODDO BHF lowers the price target for GRENKE from EUR 27.30 to EUR 18.30. Neutral. $GLJ (-2.32%)

- BERNSTEIN lowers the price target for KERING from EUR 260 to EUR 220. Market Perform. $KER (-2.79%)

- BERNSTEIN lowers the price target for LVMH from EUR 795 to EUR 700. Outperform. $MC (-1.45%)

- BERNSTEIN lowers the price target for VESTAS from DKK 250 to DKK 215. Outperform. $VWS (-1.56%)

- JEFFERIES lowers the price target for SMA SOLAR from EUR 19 to EUR 14. Hold. $S92 (-4.19%)

- JEFFERIES lowers the price target for VERBIO from EUR 27 to EUR 22. Buy. $VBK (-3.86%)

- JEFFERIES lowers the price target for PVA TEPLA from EUR 14.50 to EUR 12. Hold. $TPE (-1.04%)

- HSBC downgrades TARGET to Hold. Target price USD 138. $TGT (-0.28%)

- UBS lowers the price target for BAYER from EUR 30 to EUR 22. Neutral. $BAYN (-0.12%)

The most interesting from the $NVDA (+2.92%) Earnings, Singapore on the 2.

21.11.2024

Nvidia continues to grow explosively thanks to AI boom + DATAGROUP with preliminary figures TOP + Novartis aims for slightly stronger growth in the medium term

The AI boom is a boon for the chip group Nvidia $NVDA (+2.92%) has become a goldmine - and the business is getting bigger and bigger. In the last quarter, turnover shot up by 94 percent year-on-year to 35.1 billion dollars (33.3 billion euros). Profit more than doubled to 19.3 billion dollars. At the same time, investors had hoped for an even better forecast for the current quarter. The shares of the world's most valuable company, with a market capitalization of around 3.5 trillion dollars, fell by 2.5 percent in US after-hours trading. The AI boom has become a goldmine for the chip company Nvidia - and the business is getting bigger and bigger. In the last quarter, turnover shot up by 94 percent year-on-year to 35.1 billion dollars (33.3 billion euros). Profit more than doubled to 19.3 billion dollars. At the same time, investors had hoped for an even better forecast for the current quarter. The shares of the world's most valuable company, with a market capitalization of around 3.5 trillion dollars, fell by 2.5 percent in US after-hours trading. The next chip generation is on its way!

DATAGROUP $D6H (-1.72%) reaches the upper end of guidance according to preliminary figures for FY 2023/2024

• Total revenue in FY 2023/2024 up 6.0 % to EUR 527.6m
• Continued strong development in CORBOX core business
• Continued increase in quarterly sales: sales in the fourth quarter of 2023/2024 up 14.8% on the previous year, organic growth of around 8.0
• EBIT in the 2023/2024 financial year also at the upper end of the forecast at EUR 45.8 million
• EBIT margin at 8.7% as planned, characterized by investments in future technologies
• Comprehensive package adopted to increase shareholder value

The Swiss pharmaceutical group Novartis $NOVN (+0.86%) expects slightly more growth in the medium term than before following its reorganization. In the period from 2023 to 2028, Group sales are expected to increase by an average of 6 percent annually instead of the previously targeted 5 percent, the company announced on Thursday at an investor day. With the new forecast, the Group's top management led by CEO Vasant Narasimhan is relying on the strong growth momentum of the brands already on the market, among other things. Together, these brands have the potential to generate more than 3 to more than 8 billion US dollars a year at peak times. In addition, the Group is about to submit marketing authorization applications for more than 15 additional drugs. The Basel-based company also points to a well-filled research pipeline with more than 30 drugs in testing, which should enable sales growth in the mid-single-digit range even after 2029. Meanwhile, Novartis is still aiming for an adjusted operating margin of more than 40 percent by 2027. The Swiss pharmaceutical giant has now transformed itself into a company specializing purely in innovative medicines. The focus is on the four therapeutic areas of cardiovascular, renal and metabolic diseases, immunology, neurology and oncology

Thursday: Stock market dates, economic data, quarterly figures

ex-dividend of individual stocks

Microsoft USD 0.83

Vodafone Group USD 0.02

Applied Materials USD 0.40

Quarterly figures / company dates USA / Asia

12:30 PDD Holdings quarterly figures

14:00 GE Healthcare Technologies Investor Day

No time specified: Intuit | Gap | Deere & Co quarterly figures | ResMed AGM

Quarterly figures / Company dates Europe

07:00 Julius Baer Group 10 months results

07:30 CTS Eventim quarterly figures

08:00 DFV Deutsche Familienversicherung AG Quarterly figures

Economic data

• 08:00 DE: Insolvencies
• 08:45 FR: Business Climate Index November PROGNOSIS: 97 previous: 97
• 12:00 TR: Turkish Central Bank, outcome of the Monetary Policy Council meeting Key interest rate FORECAST: n/a previously: 50.00%
• 14:30 US: Initial jobless claims (week) FORECAST: 220,000 Previous: 217,000
• 14:30 US: Philadelphia Fed Index November PROJECTED: 8.2 PREVIOUS: 10.3
• 16:00 US: Leading Indicators Index October FORECAST: -0.4% yoy previous: -0.5% yoy
• 16:00 US: Existing Home Sales October FORECAST: +2.9% yoy previous: -1.0% yoy
• 16:00 EU: Eurozone Consumer Confidence Index (flash estimate) November FORECAST: -12.1 previous: -12.5